FindTrial
Sign In

A Prospective Self-Controlled Study of 0.5%Topical Timolol Cream versus 595nm Pulsed-Dye-Laser Superficial Infantile Hemangiomas in Chinese Patients

A Prospective Self-Controlled Study of 0.5%Topical Timolol Cream versus 595nm Pulsed-Dye-Laser Superficial Infantile Hemangiomas in Chinese Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOB-15007282
Enrollment
Unknown
Registered
2015-10-26
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Hemangioma

Interventions

Laser:595nmPDL
Topical cream:Topical Timolol

Sponsors

Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. a proliferating IH that was diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies; 2. superficial IH with an area larger than 6 cm2; and 3. agreement to participate and signed informed consent provided by patients guardians.

Exclusion criteria

Exclusion criteria: Patients who had any contraindications or complications (e.g. ulceration, a local infection, bronchial asthma). Additional exclusion criteria included the patients with a deep component to their hemangioma or had other multiple treatments before

Design outcomes

Primary

MeasureTime frame
Skin Color;Lesion Area;—

Countries

China

Contacts

Public ContactHanru YING
yinghanru@126.com+86 13020198669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026